Dupixent® (dupilumab) sbla accepted for fda priority review for the targeted treatment of bullous pemphigoid (bp)

If approved, dupixent would be the first and only targeted medicine to treat bp in the u.s.; fda decision expected by june 20, 2025

BP Ratings Summary

BP Quant Ranking